Orders from 1390 SEK Free delivery from 2895 SEK Ready for pickup dead drop: collect in 5 min Free parcel delivery from 2895 SEK

Substances · Arylcyclohexylamines

FXE (Fluorexetamine)

C14H18FNO CAS 2850352-64-4 Analytical reference material — not for human consumption
Preferred name
FXE (Fluorexetamine)
IUPAC name
2-(ethylamino)-2-(3-fluorophenyl)cyclohexan-1-one
Parent CAS number (reference)
2850352-64-4
Molecular formula
C14H18FNO
Molecular weight
235.3 g/mol
InChIKey
FCETYWCLCUZFJI-UHFFFAOYSA-N
PubChem
CID 137332183
Source
PubChem
Verified synonyms & catalog abbreviations
Fluorexetamine 3-F-2'-oxo-PCE FXE

Verified Neurochemical & Toxicological Intelligence

FXE (Fluorexetamine)

3-Fluoro-2'-oxo-PCE Dissociative (NMDA Antagonist) Arylcyclohexylamine
Verified PubChem & CAS Identity C14H18FNO · CAS 2850352-64-4 · CID 137332183
Calibrated Physical Form Pure Crystalline / Analytical Powder (≥98%)
≥98% Analytical Purity Verified 235.3 g/mol
Peer-Reviewed & Agency Citations 2 · verified sources

Receptor Telemetry & Mechanism of Action

NMDA Uncompetitive Channel Blockade Primary
SERT / DAT Monoamine Reuptake Tone Low

Fluorexetamine acting as a brisk, clear-headed NMDA channel blocker intermediate in potency between 2-FDCK and DMXE.

Biotransformation & Active Metabolites

N-deethylation via hepatic CYP enzymes.

Temporal Pharmacokinetics

3-Fluoro-2'-oxo-PCE Dissociative (NMDA Antagonist) — More energetic and colorful than 2-FDCK while shorter and cleaner on recovery than O-PCE or DCK.

  1. Onset 15–35 min
  2. Peak Window 1–2 h
  3. Total Window 2.5–4.5 h
  4. Residual / Half-Life 2–5 h residual

More energetic and colorful than 2-FDCK while shorter and cleaner on recovery than O-PCE or DCK.

Quantitative Response Spectrum (Published Literature)

Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.

Threshold
10–20 mg
Cognitive & Sensory

Subtle threshold receptor activity (3-Fluoro-2'-oxo-PCE Dissociative (NMDA Antagonist)).

Somatic & Autonomic

Minimal baseline autonomic shift.

Light
20–40 mg
Cognitive & Sensory

Mild, clear-headed expression of primary class profile.

Somatic & Autonomic

Light somatic modulation.

Common Reference
40–75 mg
Cognitive & Sensory

Full characteristic neurochemical and perceptual profile documented in literature.

Somatic & Autonomic

Moderate somatic relaxation, ataxia, or autonomic tone depending on class.

Strong
75–110 mg
Cognitive & Sensory

Pronounced intensity, cognitive/motor impairment, or deep immersion.

Somatic & Autonomic

Marked somatic load and heightened adverse-event sensitivity.

Heavy / Toxic Zone
120+ mg
Cognitive & Sensory

Amnesia, blackout, acute dysphoria, confusion, or anesthetic dissociation.

Somatic & Autonomic

High toxicity zone: severe motor loss, cardiovascular strain, or respiratory hazard.

Interaction Matrix & Critical Contraindications

Critical Hazard — Never Combine

Alcohol, Opioids (O-DSMT), Benzodiazepines, and GHB/GBL

Severe ataxia, unconsciousness, respiratory depression, and fatal vomiting aspiration.

Elevated Hazard — Avoid

Strong Stimulants (Cathinones, Cocaine, Amphetamines)

Compounds hypertension, tachycardia, manic disorientation, and psychotic episodes.

Caution / Receptor Attenuation

Cannabis & Psychedelics

Dramatically intensifies dissociation, confusion, and sensory immersion.

Structural Isomer & Sibling Comparison

More energetic and colorful than 2-FDCK while shorter and cleaner on recovery than O-PCE or DCK.

Physicochemical Stability & Storage

Physical Form: White to off-white crystalline powder or fine crystals. · Soluble in water, ethanol, and saline.

Chemically stable when kept dry, sealed, and protected from light at room temperature.

Cross-Tolerance & Dependence Profile

Slowly decaying NMDA cross-tolerance shared across all arylcyclohexylamines (halves in ~3–7 days, full baseline 2+ weeks). Chronic frequent exposure carries documented urological/bladder epithelial toxicity.

Codes on this card

Short meanings for the abbreviations printed with this substance.

Open the full glossary →
DAT Dopamine transporter

DAT is the protein that collects dopamine back from the gap between nerve cells. A card that names DAT is quoting a laboratory result about that protein.

SERT Serotonin transporter

SERT is the protein that collects serotonin back into the nerve cell. A higher number than at DAT means the serotonin transporter needed more concentration to reach the halfway point.

NMDA NMDA glutamate channel

NMDA is a glutamate receptor that works like a gated channel. Ketamine-type and PCP-type cards cite it when papers describe that channel as blocked.

EC₅₀ / IC₅₀ Halfway concentration

EC50 is the concentration where a lab saw half of the maximum measured effect. IC50 is the concentration where it saw half of the maximum block. Smaller means that halfway point came at a lower concentration.

Kᵢ Binding tightness in nanomoles

Ki says how tightly a compound sits on a receptor in a binding test. It is written in nanomoles per litre. A Ki of 1 nM means very tight binding in that experiment.

ratio Selectivity ratio

A selectivity ratio divides two halfway numbers, such as SERT EC50 by DAT EC50, to show which target the assay reached first. The direction of the division has to be stated, or the number flips.

T½ Half-life

Half-life is the time it takes a measured concentration to fall by half. After one half-life, half remains. After another, a quarter of the original measurement remains.

Tolerancja × Cross-Tolerance

When exposure to one compound reduces sensitivity to other compounds that act on the same receptor family (for example across all 5-HT2A lysergamides or all GABA-A modulators).

Comprehensive Analytical & Toxicological Monograph

FXE (Fluorexetamine) (2-(ethylamino)-2-(3-fluorophenyl)cyclohexan-1-one; CAS 2850352-64-4, PubChem CID 137332183) is a arylcyclohexylamine reference compound (C14H18FNO, 235.3 g/mol) classified pharmacologically as a 3-Fluoro-2'-oxo-PCE Dissociative (NMDA Antagonist). Fluorexetamine acting as a brisk, clear-headed NMDA channel blocker intermediate in potency between 2-FDCK and DMXE. N-deethylation via hepatic CYP enzymes. In published observational and toxicological literature, threshold response is noted at 10–20 mg, light range at 20–40 mg, common reference range at 40–75 mg, strong intensity at 75–110 mg, and heavy/adverse territory at 120+ mg, with an onset of 15–35 min, peak window of 1–2 h, and total duration of 2.5–4.5 h (2–5 h residual). More energetic and colorful than 2-FDCK while shorter and cleaner on recovery than O-PCE or DCK. Critical contraindications include Alcohol, Opioids (O-DSMT), Benzodiazepines, and GHB/GBL.

Chemical Architecture & Structural Profile

FXE (Fluorexetamine) (2-(ethylamino)-2-(3-fluorophenyl)cyclohexan-1-one) is a reference compound belonging to the Arylcyclohexylamines class, characterized by the molecular formula C14H18FNO and a molar mass of 235.3 g/mol. The parent molecule is indexed under CAS registry number 2850352-64-4 and in the NCBI PubChem database as CID 137332183 (Standard InChIKey: FCETYWCLCUZFJI-UHFFFAOYSA-N).

Citations

Reference Toxicology & Safety Profile

In documented chemical and harm-reduction literature (PubChem / PsychonautWiki, CC BY 4.0), FXE (Fluorexetamine) is indexed within the Arylcyclohexylamines structural group. Arylcyclohexylamine derivative; toxicological literature highlights severe hazard interactions when combined with central nervous system depressants (alcohol, GHB/GBL, opioids, benzodiazepines). Standard laboratory handling precautions—including nitrile gloves, eye protection, and local exhaust ventilation—apply whenever handling the reference material.

Citations

Analytical Use & Laboratory Notice

This reference sheet provides chemical, analytical, and toxicological provenance only. The material is strictly not for human consumption, diagnostic, or veterinary use. Research-use labelling does not establish legal status in any jurisdiction.

Citations